Global Retinopathy Of Prematurity Therapeutics
Market Report
2025
Retinopathy Of Prematurity Therapeutics Market Report 2025 (Global Edition)
Retinopathy of Prematurity Therapeutics market size was $749.70 Million in 2024 and it is forecasted to reach $1,049.56 Million by the end of 2030. Retinopathy of Prematurity Therapeutics Industry's Compound Annual Growth Rate will be 5.70% from 2024 to 2031.
The base year for the calculation is 2023 and 2019 to 2023 will be historical period. The year 2024 will be estimated one while the forecasted data will be from year 2025 to 2031. When we deliver the report that time we updated report data till the purchase date.
PDF Access: Password protected PDF file, Excel File Access: Quantitative data, PPT Report Access: For the presentation purpose, Cloud Access: Secure Company Account Access.
| Share your contact details to receive free updated sample copy/pages of the recently published edition of Retinopathy Of Prematurity Therapeutics Market Report 2024.
Global Retinopathy Of Prematurity Therapeutics Market Report 2024 Market Size Split by Type (Laser Treatment, Injection, Eye Surgery, Others), by Application (Hospital, Clinic, Home Care), by End-User...
As per Cognitive Market Research's latest published report, the Global Retinopathy of Prematurity Therapeutics market size was $749.70 Million in 2024 and it is forecasted to reach $1,049.56 Million by the end of 2030. Retinopathy of Prematurity Therapeutics Industry's Compound Annual Growth Rate will be 5.70% from 2024 to 2031.
| Base Year | 2023 |
| Historical Data Time Period | 2019-2023 |
| Forecast Period | 2024-2031 |
| Global Retinopathy Of Prematurity Therapeutics Market Compound Annual Growth Rate (CAGR) for 2024 to 2031 | 5.7% |
| Market Split by Type |
|
| Market Split by Application |
|
| Market Split by End-User |
|
| List of Competitors |
|
| Regional Analysis |
|
Country Analysis |
|
Report scope is customizable as we have a huge database of Retinopathy Of Prematurity Therapeutics industry. We can deliver an exclusive report Edition/Consultation as per your data requirements. Request for your Free Sample Pages.
Retinopathy Of Prematurity Therapeutics Market is Segmented as below. Particular segment of your interest can be provided without any additional cost. Download the Sample Pages!
Retinopathy Of Prematurity Therapeutics Market Report Description
What is Retinopathy of Prematurity Therapeutic?
Retinopathy of prematurity (ROP) is the abnormal development of blood vessels in the retina of the eye. It occurs in infants born prematurely. Retinopathy of prematurity is a bilateral disease of abnormal retinal neovascularization in preterm infants, especially those with the lowest birth weight. Retinopathy of prematurity (ROP) occurs when these blood vessels continue to grow in an abnormal pattern, forming bulges of tissue between the vascularized central retina and the non-vascularized peripheral retina.
Retinopathy of prematurity (ROP) usually affects infants weighing less than 100 grams. 1500g or more 30th week of gestation at birth, particularly for those with serious medical complications or those on excessive and prolonged oxygen therapy. There are two ways to treat retinopathy in preterm infants. In severe retinopathy of prematurity, ablation of the peripheral anti-vascular retina by laser photocoagulation reduces the incidence of retinal folds and detachment. Another treatment is bevacizumab. Bevacizumab, a monoclonal antibody against vascular endothelial growth factor can stop the progression of retinopathy of prematurity. Compared with laser treatment, bevacizumab has a lower recurrence rate and fewer structural abnormalities in some cases. Along with this, in freezing treatment (cryotherapy), the surgeon uses a freezing-cold instrument to terminate the part of the retina.
The increasing prevalence of eye disease along with the rise in R&D activities on medications for retinopathy of prematurity (ROP) from therapeutic companies is the major driving factor for the retinopathy of the prematurity therapeutics market during the forecast period. With limited resources for oxygen delivery and monitoring techniques, mature preterm infants are developing serious levels of ROP in developing countries. Therefore, anti-VEGF medications are now increasingly used to treat ROP. These drugs are inserted into the eye to stop unwanted blood vessel growth. For example, The National Eye Institute estimated that nearly 14,000–16,000 preterm infants in the USA annually have some symptoms of ROP. Annually, approximately 4001600 infants in the USA are blind from retinopathy of prematurity.
Furthermore, the recent development of improved imaging techniques and the introduction of advanced technological infrastructure has led to the increased use of telemedicine and medical professionals are increasing the use of artificial intelligence to improve access to care for children at risk of developing ROP. Healthcare providers have shifted their focus from laser therapy to now having the choice of anti-vascular endothelial growth factor (VEGF) therapy for the further treatment of ROP.
With the increasing incidence of ROP, there is a growing need for affordable and easy-to-use screening techniques for the appropriate identification of at-risk infants. Telemedicine for ROP is being implemented in many parts of the world, and artificial intelligence (AI) is now being explored as a means of improving access to care. Additionally, the telemedicine program has enabled the development of non-physician training programs and AI techniques for ROP diagnosis by collecting digital images captured during telemedicine sessions for use in training. All these factors are influencing the demand for the retinopathy of prematurity therapeutics market.
Retinopathy Of Prematurity Therapeutics Market Size
Market Dynamics of the Retinopathy of Prematurity Therapeutic Market
Market Drivers Retinopathy of Prematurity Therapeutic Market
- Rising prevalence of retinopathy of prematurity
ROP is a condition where the blood vessels in a newborn baby's eyes grow improperly. ROP mainly affects preterm newborns, and the earlier the baby is born, the greater the chance of having the illness. Babies born more than 12 weeks early are most likely to have ROP.
ROP damages the retina, which is the tissue that lines the back of the eye and conveys visual information to the brain. A blood supply is necessary for the retina to operate correctly. Blood arteries that supply the retina with blood expand while a newborn develops within the womb. Typically, this development is finished a few weeks before delivery. The retina's blood vessels are still in the early stages of development when a newborn is delivered prematurely. As a result, following birth, the vessels could grow abnormally.
In extreme circumstances, the retina may suffer damage from blood and scar tissue. In the worst situations, this can make a baby's vision worse or even make them blind. Each year, 3.9 million babies are born in the United States. ROP affects around 14,000 people, 90% of whom only have a minor illness. Each year in the United States, 400–600 newborns are born with ROP, which causes them to go legally blind, and around 1,100–1,500 people have conditions severe enough to require medical attention.
According to research conducted by the Baylor College of Medicine, ROP accounts for between 6 and 18 percent of all juvenile blindness in affluent nations. At least half of infants with ROP who are through Stage 3 experience severe eye impairment. Similar to this, ROP causes irreversible vision damage in around 32,300 newborns globally each year, of whom about 20,000 go blind or have a severe visual impairment. This necessitates the treatment of retinopathy of prematurity.
Many infants with ROP have minor cases that improve on their own. Nonetheless, some infants require therapy to prevent the progression of ROP. Options for treatment include:
• Laser therapy - Infants with severe ROP may require retinal side laser therapy. This medication can help prevent the progression of ROP and safeguard the child's vision.
• Injections - Doctors can also inject treatments called anti-VEGF therapies into the baby's eye. These drugs prevent the development of new blood vessels.
• Eye surgery - For infants with partly or fully detached retinas (stages 4 or 5), there are two forms of retina surgery: Scleral buckling surgery and Vitrectomy.
As a result, rising prevalence of retinopathy of prematurity drives the growth of the retinopathy of prematurity therapeutics market.
- Increasing spending on premature babies' health
A baby is considered preterm if it is born before 37 weeks of pregnancy. Based on gestational age, preterm birth is divided into the following subcategories:
• Preterm birth (less than 28 weeks)
• Very preterm birth (28 to 32 weeks)
• Moderate-to-late gestation (32 to 37 weeks)
Preterm births can occur spontaneously or when it is necessary to arrange an early cesarean delivery or induction of labor due to a medical condition. There are several causes of preterm birth.
The World Health Organization estimates that 15 million infants are born prematurely each year. Complications from preterm delivery are the biggest cause of mortality in children under the age of five, accounting for almost 1 million fatalities in 2015. Preterm birth rates vary significantly between nations, ranging from 5% to 18% of all births.
Babies that are born prematurely may not develop all the organs completely. They may require a lengthier hospital stay and experience more health issues than babies delivered later. As a result, spending on preterm newborns' health is rising rapidly.
The March of Dimes reports that a preterm newborn spends an average of 25.4 days in a specialty care nursery, at a cost of $144,692. Preterm birth costs the US healthcare system an additional $26.2 billion annually. According to recent research from the March of Dimes Foundation, the average cost of medical treatment for a preterm or low birth weight infant during the first year of life is roughly $49,000.
This expenditure was further encouraged by active government assistance. For instance, in India, the National Program for Control of Blindness and Visual Impairment (NPCB and VI), Rashtriya Bal Swasth Karyakram (RBSK), and Child Health include all the services required for the healthy survival of babies, including the prevention of blindness due to ROP.
This increasing spending on premature babies' health boosts the growth of the retinopathy of the prematurity therapeutics market.
Restraints for Retinopathy of Prematurity Therapeutics Market
-
Dearth of skilled ophthalmologists. (Access Detailed Analysis in the Full Report Version)
Opportunities for Retinopathy of Prematurity Therapeutics Market
-
Upsurge in the research and development activities. (Access Detailed Analysis in the Full Report Version)
COVID-19 Impact on Retinopathy of Prematurity Therapeutics Market
The COVID-19 impact on the retinopathy of the prematurity therapeutics market was affected negatively on account of the delayed medical procedures that caused irreversible blindness in premature babies, fear of catching the COVID-19 virus and several restrictions and protocols in hospitals contributed to the reduced numbers of babies screened for retinopathy of the prematurity.
The coronavirus pandemic has had detrimental effects on healthcare systems around the world. All elective and emergency services are at a standstill following the nationwide lockdown. Retinopathy of prematurity (ROP) is an emergency eye condition for which screening of all preterm and low birth weight newborns is critical. Travel restrictions, social distancing measures, and the need to conserve medical resources may limit ROP access to infant care, especially in areas with limited medical infrastructure.
Disruptions of follow-up care led to a slowdown in ROP treatment. Regular follow-up appointments with a pediatric ophthalmologist are important to monitor ROP progress and adjust treatment as needed. The pandemic may have interrupted these follow-up appointments, which may have worsened outcomes for affected infants. Hence, the COVID-19 pandemic has had a significant impact on the retinopathy of the prematurity therapeutics market.
We have various report editions of Retinopathy Of Prematurity Therapeutics Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.
Competitive Landscape of the Retinopathy of Prematurity Therapeutic Market
SignaBlok, Inc
SignaBlok, Inc is a biopharmaceutical company, which is engaged in developing novel mechanism-based targeted therapeutics and delivery nanosystems using revolutionary science and technologies. The company offers a wide range of technologies including technology signaling chain homooligomerization platform basics, macrophage modulation, and macrophage imaging. SignaBlok, Inc focuses on a wide array of therapeutic areas that include,
• Cancer
• Autoimmune Diseases
• Retinopathy
• Atherosclerosis
• Sepsis/ARDS & COVID
• Other Inflammatory Diseases
D.Western Therapeutics Institute, Inc
D. Western Therapeutics Institute, Inc. is engaged in discovering and developing new drugs. Its pipeline products include Ripasudil hydrochloride hydrate, H-1337, DW-1001, DW-1002, DW-5LBT, treatment for retinopathy of prematurity and others.
Top Companies Market Share in Retinopathy Of Prematurity Therapeutics Industry: (In no particular order of Rank)
- SignaBlok Inc
- D.Western Therapeutics Institute Inc
- RECORDATI S.p.A
- Novartis AG
- Novelty Nobility Inc.
- Regeneron Pharmaceuticals Inc.
- AyuVis Research Inc
- AyuVis Research Inc.
- AntlerA
- Confidential Data
- Access The Paid Version
- Data Hidden
If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.
Regional Analysis of the Retinopathy of Prematurity Therapeutics Market
Based on geographical analysis, the market of retinopathy of prematurity therapeutics is segmented into North America, Asia Pacific, Europe, Latin America, and MEA.
North America is dominating the retinopathy of prematurity therapeutics market in the forecasted period. This is owing to the rising number of babies with retinopathy of prematurity. ROP prevalence has been increasing exponentially in recent years. The study found that around 1,100 to 1,500 (or 10%) of the 14,000 preterm infants born in the U.S. each year with ROP experience severe symptoms and require medical intervention. 400–600 babies with ROP develop legal blindness.
Similar to this, the expanding healthcare sector primarily drives the retinopathy of prematurity therapeutics market in North America. The government has also given several insurance policies for paediatric healthcare. This further boosts the demand for retinopathy of prematurity therapeutics.
Asia Pacific is growing at a high CAGR in the retinopathy of prematurity therapeutics market which is attributed to the rising number of premature babies. There are over 15 million preterm births each year throughout the world, with India having the highest rate. The increase in adolescent delivery rates is one of the significant causes for the rise in the number of premature deliveries.
The current report Scope analyzes Retinopathy Of Prematurity Therapeutics Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com
- North America (United States, Canada, Mexico)
- Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
- Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
- South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
- Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)
Retinopathy Of Prematurity Therapeutics Market Share (%) by Region (2019-2031)
The above graph is for illustrative purposes only.
To learn more about geographical trends request the free sample pages.
Get Free Sample
Retinopathy Of Prematurity Therapeutics Market Analysis
Global Retinopathy Of Prematurity Therapeutics Market Report 2024 Edition talks about crucial market insights with the help of segments and sub-segments analysis. In this section, we reveal an in-depth analysis of the key factors influencing Retinopathy Of Prematurity Therapeutics Industry growth. Retinopathy Of Prematurity Therapeutics market has been segmented with the help of its Type, Application End-User, and others. Retinopathy Of Prematurity Therapeutics market analysis helps to understand key industry segments, and their global, regional, and country-level insights. Furthermore, this analysis also provides information pertaining to segments that are going to be most lucrative in the near future and their expected growth rate and future market opportunities. The report also provides detailed insights into factors responsible for the positive or negative growth of each industry segment.
Retinopathy of Prematurity Therapeutics Segment by Type
Laser Treatment
In 2018, the Laser Treatment Segment Revenue was USD 423.28 Million, and it expected to reach at USD 630.62 Million in 2030
Endoscopic. Laser treatment held a major revenue share in terms of type as laser treatment is one of the main treatment procedures for retinopathy of prematurity (ROP). During the procedure, a special laser is used to target and destroy the abnormal blood vessels in the retina. This helps to prevent further damage and can improve the chances of preserving vision. The laser treatment for ROP is usually done under anesthesia and can be performed on an outpatient basis. The procedure itself is relatively quick, taking only about 10-20 minutes to complete. After the treatment, the baby will need to be monitored under supervision to ensure that the condition does not progress. It's important to consider that while laser treatment can be effective in treating ROP, it does not always completely restore vision.
Injection
The injection segment is growing at the highest CAGR during the forecast period. This is because of the recent advancements in anti-VEGF drugs to treat ROP. Healthcare providers can inject medicines called anti-VEGF drugs into a baby’s eye. These medicines work by blocking the growth of blood vessels. The treatment option for ROP is the injection of medication directly into the eye. The medication used is usually an anti-VEGF drug, which helps to stop the abnormal blood vessels from growing and causing further damage to the retina. The injection is performed in a sterile environment under local anesthesia. The medication is injected into the vitreous humor, which is the clear gel-like substance inside the eye. The injection itself takes only a few minutes.
Eye Surgery
There are two types of retinal surgery for babies with partial or complete retinal detachment. The first surgery is scleral buckle surgery. The doctor places a flexible band around the sclera. The band holds the detached retina until the eye begins to grow normally, and the doctor will remove it. Another surgery is a vitrectomy, the doctor makes small openings in the eye wall to remove most of the vitreous and replace it with a saline solution. The doctor then removes the scar tissue on the retina.
Others
Cryotherapy, oxygen therapy and phototherapy are other treatment options available for retinopathy of prematurity (ROP). Cryotherapy treatment involves using a probe to freeze the peripheral retina, which helps to destroy the abnormal blood vessels. Another therapy is oxygen therapy which can be used to help prevent the development of ROP in premature infants. However, it is important to closely monitor oxygen levels to prevent them from becoming too high or too low, which can increase the risk of ROP.
- Laser Treatment
- Injection
- Eye Surgery
- Others
Retinopathy Of Prematurity Therapeutics Market Share (%) by Type in 2019-2031
The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Retinopathy Of Prematurity Therapeutics Industry. Request a Free Sample PDF!
Retinopathy of Prematurity Therapeutics Segment by Application
Hospital
In 2018, the Hospital Segment Revenue in Retinopathy of Prematurity Therapeutics was USD 483.16 Million, and it will reach USD 702.14 Million in 2030. Based on application, the hospital segment is dominant in 2022, as diagnosis of ROP is increasingly performed in hospitals by trained medical professionals. In hospitals, ROP is typically diagnosed and managed by a team of healthcare professionals, including neonatologists, ophthalmologists, and nurses. The diagnosis of ROP is made by a pediatric ophthalmologist who performs a comprehensive eye exam to look for signs of abnormal blood vessel growth in the retina. This examination is done a few weeks after birth and then repeated at regular intervals depending on the severity of the ROP.
Clinic
The clinic segment is growing at the highest CAGR during the forecast period due to the extensive availability of ROP treatment procedures. In clinics, ROP is diagnosed by a team of healthcare professionals, including pediatric ophthalmologists and nurses. If ROP is detected, the pediatric ophthalmologist develops a treatment plan based on the severity of the condition. The standard treatment for ROP is laser therapy, which involves using a laser to destroy the abnormal blood vessels in the retina.
Home Care
Home care is providing a supportive and nurturing home environment that can play an important role in promoting the health and well-being of premature infants with ROP. It is important for parents and caregivers to stay informed about the condition and to seek out support. This may include working closely with the healthcare team to develop a treatment plan, attending regular follow-up appointments with the pediatric ophthalmologist, and following counselling services to help cope with the emotional challenges of caring for a child with ROP.
- Hospital
- Clinic
- Home Care
Retinopathy Of Prematurity Therapeutics Market Share (%) by Application in 2019-2031
2019
2023
2031
The above Graph is for representation purposes only. This chart does not depict actual Market share.
To learn more about market share request the free sample pages.
Get Free Sample
Retinopathy Of Prematurity Therapeutics End-User Segment Analysis
- Hospitals
- Ophthalmic Clinics
- Ambulatory Surgical Centers
Author's Detail
Manjiri KanhereSenior Research Associate at Cognitive Market Research
Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over 3+ years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies. Her expertise lies in the ability to analyze complex data sets and deliver insights that drive business decisions. At Cognitive Market Research, she handles the market research related to Pharma and healthcare industry.
Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over three years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies.
In her current role, Manjiri handles the market research related to Pharma and healthcare industry. Her passion lies in utilizing innovative approaches to distill complex information into strategic insights that empower organizations to make informed decisions.Manjiri remains an invaluable asset in the dynamic landscape of market research.
Author's Conclusion
- Author says: CAGR from 2023-2030 is expected to be: 5.70%
- The rising prevalence of retinopathy of prematurity and increasing spending on premature babies’ health accelerates the growth of the retinopathy of prematurity therapeutics market
- The dearth of a skilled ophthalmologists can impede the growth of the retinopathy of the prematurity market in the forecasted period
Frequently Asked Questions
Please note, we have not disclose, all the sources consulted/referred during a market study due to confidentiality and paid service concern. However, rest assured that upon purchasing the service or paid report version, we will release the comprehensive list of sources along with the complete report and we also provide the data support where you can intract with the team of analysts who worked on the report.
Latest News about Retinopathy Of Prematurity Therapeutics Market
Sources from Pharma & Healthcare Industry
- https://en.wikipedia.org/wiki/American_Society_for_Pharmacy_Law
- https://en.wikipedia.org/wiki/American_Society_of_Consultant_Pharmacists
- https://en.wikipedia.org/wiki/American_Society_of_Health-System_Pharmacists
- https://www.apsm-uk.com/
- https://en.wikipedia.org/wiki/Australasian_College_of_Pharmacy
- https://en.wikipedia.org/wiki/American_Association_of_Colleges_of_Pharmacy
- https://en.wikipedia.org/wiki/American_College_of_Clinical_Pharmacy
- https://en.wikipedia.org/wiki/American_Pharmacists_Association
- https://www.bio.org/
- https://en.wikipedia.org/wiki/Canadian_Pharmacists_Association
- https://en.wikipedia.org/wiki/Canadian_Society_of_Hospital_Pharmacists
- https://en.wikipedia.org/wiki/Chinese_Pharmaceutical_Association
- https://en.wikipedia.org/wiki/American_Association_of_Psychiatric_Pharmacists
- https://en.wikipedia.org/wiki/Danish_Association_of_Pharmaconomists
- https://en.wikipedia.org/wiki/EPhEU
- https://www.fda.gov/
- https://www.gmc-uk.org/
- https://www.ifpma.org/
- https://www.fip.org/
- https://en.wikipedia.org/wiki/International_Pharmaceutical_Students%27_Federation
- https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency
- https://en.wikipedia.org/wiki/National_Pharmacy_Association
- https://en.wikipedia.org/wiki/Norwegian_Pharmacy_Association
- https://en.wikipedia.org/wiki/Canadian_Pharmacists_Journal#History
- https://en.wikipedia.org/wiki/Pakistan_Pharmacists_Association
- https://en.wikipedia.org/wiki/Pharmaceutical_Association_of_Mauritius
- https://en.wikipedia.org/wiki/Pharmaceutical_Group_of_the_European_Union
- https://en.wikipedia.org/wiki/Pharmaceutical_Society_of_Australia
- https://en.wikipedia.org/wiki/Pharmaceutical_Society_of_New_Zealand
- https://en.wikipedia.org/wiki/Pharmaceutical_Society_of_Northern_Ireland
- https://en.wikipedia.org/wiki/Professional_Compounding_Centers_of_America
- https://en.wikipedia.org/wiki/Royal_Pharmaceutical_Society
- https://www.aaps.org/home
- https://www.bioindustry.org/
- https://www.controlledreleasesociety.org/
- https://www.efpia.eu/
- https://www.epemed.org/online/www/content/ENG/index.html
- https://icr-global.org/
- https://ispe.org/
- https://en.wikipedia.org/wiki/Pharmaceutical_Association_of_Israel
- https://www.phrma.org/
- https://en.wikipedia.org/wiki/The_Pharmacy_Guild_of_Australia
- https://en.wikipedia.org/wiki/The_Society_of_Hospital_Pharmacists_of_Australia
- https://en.wikipedia.org/wiki/Healthcare_industry
- https://www.pharma-iq.com/business-development/articles/top-50-pharmaceutical-blogs-and-publications
- https://www.pharmatimes.com/news
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7967517/
- https://www.cbo.gov/publication/57126
- http://: https://www.who.int/tools/atc-ddd-toolkit/data
- https://www.oecd.org/els/health-systems/health-data.htm
- https://www.bls.gov/ooh/healthcare/home.htm
- https://data.worldbank.org/topic/8
- https://www.statnews.com/about/
- https://www.health.pa.gov/topics/HealthStatistics/Pages/health-statistics.aspx
- https://www.cdc.gov/nchs/index.htm
- https://www.aha.org/statistics/fast-facts-us-hospitals
- https://www.census.gov/library/publications/2021/demo/p60-274.html
- https://www.adb.org/what-we-do/sectors/health/main
Retinopathy Of Prematurity Therapeutics Market Report Table of Content
Disclaimer:
- This is just a redacted sample pages of the actual deliverable report and only for representative purposes
- Charts/Graphs/Numbers/data are only for Representative purposes and do not depict actual statistics.
- The table of Contents differs according to the user License selection. Current Displayed TOC is for the Corporate User License Report Edition. TOC Customization options: Add or Remove section/s Or chapter/s from the report.
- Specific Tables, Graphs, Sections, and Chapters can be ordered at a discounted price.
- If applicable; On Request Volume Data will also be provided (at an Additional Cost).
| Type | Laser Treatment, Injection, Eye Surgery, Others |
| Application | Hospital, Clinic, Home Care |
| End-User | Hospitals, Ophthalmic Clinics, Ambulatory Surgical Centers |
| List of Competitors | SignaBlok Inc, D.Western Therapeutics Institute Inc, RECORDATI S.p.A, Novartis AG, Novelty Nobility Inc., Regeneron Pharmaceuticals Inc., AyuVis Research Inc, AyuVis Research Inc., AntlerA |
This chapter will help you gain GLOBAL Market Analysis of Retinopathy Of Prematurity Therapeutics. Further deep in this chapter, you will be able to review Global Retinopathy Of Prematurity Therapeutics Market Split by various segments and Geographical Split.
Chapter 1 Global Market Analysis
-
1.1 Global Retinopathy Of Prematurity Therapeutics Revenue Market Size, Trend Analysis 2019 - 2031
-
1.2 Global Retinopathy Of Prematurity Therapeutics Market Size By Regions 2019 - 2031
Global Market has been segmented on the basis 5 major regions such as North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America.
-
1.2.1 Global Retinopathy Of Prematurity Therapeutics Revenue Market Size By Region
-
-
1.3 Global Retinopathy Of Prematurity Therapeutics Market Size By Type 2019 -2031
-
1.3.1 Laser Treatment Market Size
-
1.3.2 Injection Market Size
-
1.3.3 Eye Surgery Market Size
-
1.3.4 Others Market Size
-
-
1.4 Global Retinopathy Of Prematurity Therapeutics Market Size By Application 2019 -2031
-
1.4.1 Hospital Market Size
-
1.4.2 Clinic Market Size
-
1.4.3 Home Care Market Size
-
-
1.5 Global Retinopathy Of Prematurity Therapeutics Market Size By End-User 2019 -2031
-
1.5.1 Hospitals Market Size
-
1.5.2 Ophthalmic Clinics Market Size
-
1.5.3 Ambulatory Surgical Centers Market Size
-
-
1.6 Global Level Competitor Analysis (Subject to Data Availability (Private Players))
-
1.7 Executive Summary Global Market (2019 vs 2024 vs 2031)
You can purchase only the Executive Summary of Global Market (2019 vs 2024 vs 2031)
-
1.7.1 Regional Market Revenue Summary 2019 vs 2024 vs 2031
-
1.7.2 Global Market Revenue Split By Type
-
1.7.3 Global Market Revenue Split By Application
-
1.7.4 Global Market Revenue Split By End-User
-
1.7.5 Global Market Dynamics, Trends, Drivers, Restraints, Opportunities
Global Market Dynamics, Trends, Drivers, Restraints, Opportunities, Only Pointers will be deliverable
-
This chapter will help you gain North America Market Analysis of Retinopathy Of Prematurity Therapeutics. Further deep in this chapter, you will be able to review North America Retinopathy Of Prematurity Therapeutics Market Split by various segments and Country Split.
Chapter 2 North America Market Analysis
-
2.1 North America Retinopathy Of Prematurity Therapeutics Market Size 2019 - 2031
-
2.1.1 North America Retinopathy Of Prematurity Therapeutics Market Size By Country 2019 - 2031
-
2.1.2 North America Retinopathy Of Prematurity Therapeutics Market Size by Type 2019 -2031
-
2.1.2.1 North America Laser Treatment Market Size
-
2.1.2.2 North America Injection Market Size
-
2.1.2.3 North America Eye Surgery Market Size
-
2.1.2.4 North America Others Market Size
-
-
2.1.3 North America Retinopathy Of Prematurity Therapeutics Market Size by Application 2019 -2031
-
2.1.3.1 North America Hospital Market Size
-
2.1.3.2 North America Clinic Market Size
-
2.1.3.3 North America Home Care Market Size
-
-
2.1.4 North America Retinopathy Of Prematurity Therapeutics Market Size by End-User 2019 -2031
-
2.1.4.1 North America Hospitals Market Size
-
2.1.4.2 North America Ophthalmic Clinics Market Size
-
2.1.4.3 North America Ambulatory Surgical Centers Market Size
-
-
This chapter will help you gain Europe Market Analysis of Retinopathy Of Prematurity Therapeutics. Further deep in this chapter, you will be able to review Europe Retinopathy Of Prematurity Therapeutics Market Split by various segments and Country Split.
Chapter 3 Europe Market Analysis
-
3.1 Europe Retinopathy Of Prematurity Therapeutics Market Size 2019 - 2031
-
3.1.1 Europe Retinopathy Of Prematurity Therapeutics Market Size By Country 2019 - 2031
-
3.1.2 Europe Retinopathy Of Prematurity Therapeutics Market Size by Type 2019 -2031
-
3.1.2.1 Europe Laser Treatment Market Size
-
3.1.2.2 Europe Injection Market Size
-
3.1.2.3 Europe Eye Surgery Market Size
-
3.1.2.4 Europe Others Market Size
-
-
3.1.3 Europe Retinopathy Of Prematurity Therapeutics Market Size by Application 2019 -2031
-
3.1.3.1 Europe Hospital Market Size
-
3.1.3.2 Europe Clinic Market Size
-
3.1.3.3 Europe Home Care Market Size
-
-
3.1.4 Europe Retinopathy Of Prematurity Therapeutics Market Size by End-User 2019 -2031
-
3.1.4.1 Europe Hospitals Market Size
-
3.1.4.2 Europe Ophthalmic Clinics Market Size
-
3.1.4.3 Europe Ambulatory Surgical Centers Market Size
-
-
This chapter will help you gain Asia Pacific Market Analysis of Retinopathy Of Prematurity Therapeutics. Further deep in this chapter, you will be able to review Asia Pacific Retinopathy Of Prematurity Therapeutics Market Split by various segments and Country Split.
Chapter 4 Asia Pacific Market Analysis
-
4.1 Asia Pacific Retinopathy Of Prematurity Therapeutics Market Size 2019 - 2031
-
4.1.1 Asia Pacific Retinopathy Of Prematurity Therapeutics Market Size By Country 2019 - 2031
-
4.1.2 Asia Pacific Retinopathy Of Prematurity Therapeutics Market Size by Type 2019 -2031
-
4.1.2.1 Asia Pacific Laser Treatment Market Size
-
4.1.2.2 Asia Pacific Injection Market Size
-
4.1.2.3 Asia Pacific Eye Surgery Market Size
-
4.1.2.4 Asia Pacific Others Market Size
-
-
4.1.3 Asia Pacific Retinopathy Of Prematurity Therapeutics Market Size by Application 2019 -2031
-
4.1.3.1 Asia Pacific Hospital Market Size
-
4.1.3.2 Asia Pacific Clinic Market Size
-
4.1.3.3 Asia Pacific Home Care Market Size
-
-
4.1.4 Asia Pacific Retinopathy Of Prematurity Therapeutics Market Size by End-User 2019 -2031
-
4.1.4.1 Asia Pacific Hospitals Market Size
-
4.1.4.2 Asia Pacific Ophthalmic Clinics Market Size
-
4.1.4.3 Asia Pacific Ambulatory Surgical Centers Market Size
-
-
This chapter will help you gain South America Market Analysis of Retinopathy Of Prematurity Therapeutics. Further deep in this chapter, you will be able to review South America Retinopathy Of Prematurity Therapeutics Market Split by various segments and Country Split.
Chapter 5 South America Market Analysis
-
5.1 South America Retinopathy Of Prematurity Therapeutics Market Size 2019 - 2031
-
5.1.1 South America Retinopathy Of Prematurity Therapeutics Market Size By Country 2019 - 2031
-
5.1.2 South America Retinopathy Of Prematurity Therapeutics Market Size by Type 2019 -2031
-
5.1.2.1 South America Laser Treatment Market Size
-
5.1.2.2 South America Injection Market Size
-
5.1.2.3 South America Eye Surgery Market Size
-
5.1.2.4 South America Others Market Size
-
-
5.1.3 South America Retinopathy Of Prematurity Therapeutics Market Size by Application 2019 -2031
-
5.1.3.1 South America Hospital Market Size
-
5.1.3.2 South America Clinic Market Size
-
5.1.3.3 South America Home Care Market Size
-
-
5.1.4 South America Retinopathy Of Prematurity Therapeutics Market Size by End-User 2019 -2031
-
5.1.4.1 South America Hospitals Market Size
-
5.1.4.2 South America Ophthalmic Clinics Market Size
-
5.1.4.3 South America Ambulatory Surgical Centers Market Size
-
-
This chapter will help you gain Middle East and Africa Market Analysis of Retinopathy Of Prematurity Therapeutics. Further deep in this chapter, you will be able to review Middle East and Africa Retinopathy Of Prematurity Therapeutics Market Split by various segments and Country Split.
Chapter 6 Middle East and Africa Market Analysis
-
6.1 Middle East and Africa Retinopathy Of Prematurity Therapeutics Market Size 2019 - 2031
-
6.1.1 Middle East and Africa Retinopathy Of Prematurity Therapeutics Market Size By Country 2019 - 2031
-
6.1.2 Middle East and Africa Retinopathy Of Prematurity Therapeutics Market Size by Type 2019 -2031
-
6.1.2.1 Middle East and Africa Laser Treatment Market Size
-
6.1.2.2 Middle East and Africa Injection Market Size
-
6.1.2.3 Middle East and Africa Eye Surgery Market Size
-
6.1.2.4 Middle East and Africa Others Market Size
-
-
6.1.3 Middle East and Africa Retinopathy Of Prematurity Therapeutics Market Size by Application 2019 -2031
-
6.1.3.1 Middle East and Africa Hospital Market Size
-
6.1.3.2 Middle East and Africa Clinic Market Size
-
6.1.3.3 Middle East and Africa Home Care Market Size
-
-
6.1.4 Middle East and Africa Retinopathy Of Prematurity Therapeutics Market Size by End-User 2019 -2031
-
6.1.4.1 Middle East and Africa Hospitals Market Size
-
6.1.4.2 Middle East and Africa Ophthalmic Clinics Market Size
-
6.1.4.3 Middle East and Africa Ambulatory Surgical Centers Market Size
-
-
Only Available with Corporate User License
Chapter 7 Top 10 Countries Analysis (Only Available with Corporate User License)
-
7.1 Country 1 Market Analysis
-
7.1.1 Country 1Retinopathy Of Prematurity Therapeutics Market Size by Type 2019 -2031
-
7.1.2 Country 1Retinopathy Of Prematurity Therapeutics Market Size by Application 2019 -2031
-
7.1.3 Country 1Retinopathy Of Prematurity Therapeutics Market Size by End-User 2019 -2031
-
-
7.2 Country 2 Market Analysis
-
7.2.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.3 Country 3 Market Analysis
-
7.3.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.4 Country 4 Market Analysis
-
7.4.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.5 Country 5 Market Analysis
-
7.5.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.6 Country 6 Market Analysis
-
7.6.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.7 Country 7 Market Analysis
-
7.7.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.8 Country 8 Market Analysis
-
7.8.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.9 Country 9 Market Analysis
-
7.9.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.10 Country 10 Market Analysis
-
7.10.1 Segmentation Analysis will be provided as shown for Country 1
-
This chapter provides an in-depth analysis of the market share among key competitors of Retinopathy Of Prematurity Therapeutics. The analysis highlights each competitor's position in the market, growth trends, and financial performance, offering insights into competitive dynamics, and emerging players.
Chapter 8 Competitor Analysis (Subject to Data Availability (Private Players))
-
8.1 Top Competitors Analysis
-
8.1.1 Top Players Ranking 2022
-
8.1.2 Global Retinopathy Of Prematurity Therapeutics Market Revenue and Share by Key Players
(Subject to Data Availability (Private Players))
-
8.1.3 Industry Mergers and Acquisition Analysis
-
8.1.4 New Product Launch Analysis
-
-
8.2 Company Profile (Data Subject to Availability)
-
8.2.1 SignaBlok Inc
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.1.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.1.2 Business Overview
-
8.2.1.3 Financials (Subject to data availability)
-
8.2.1.4 Product Types Specification
-
8.2.1.5 Business Strategy
-
8.2.1.6 S.W.O.TAnalysis
-
-
8.2.2 D.Western Therapeutics Institute Inc
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.2.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.2.2 Business Overview
-
8.2.2.3 Financials (Subject to data availability)
-
8.2.2.4 Product Types Specification
-
8.2.2.5 Business Strategy
-
8.2.2.6 S.W.O.TAnalysis
-
-
8.2.3 RECORDATI S.p.A
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.3.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.3.2 Business Overview
-
8.2.3.3 Financials (Subject to data availability)
-
8.2.3.4 Product Types Specification
-
8.2.3.5 Business Strategy
-
8.2.3.6 S.W.O.TAnalysis
-
-
8.2.4 Novartis AG
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.4.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.4.2 Business Overview
-
8.2.4.3 Financials (Subject to data availability)
-
8.2.4.4 Product Types Specification
-
8.2.4.5 Business Strategy
-
8.2.4.6 S.W.O.TAnalysis
-
-
8.2.5 Novelty Nobility Inc.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.5.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.5.2 Business Overview
-
8.2.5.3 Financials (Subject to data availability)
-
8.2.5.4 Product Types Specification
-
8.2.5.5 Business Strategy
-
8.2.5.6 S.W.O.TAnalysis
-
-
8.2.6 Regeneron Pharmaceuticals Inc.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.6.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.6.2 Business Overview
-
8.2.6.3 Financials (Subject to data availability)
-
8.2.6.4 Product Types Specification
-
8.2.6.5 Business Strategy
-
8.2.6.6 S.W.O.TAnalysis
-
-
8.2.7 AyuVis Research Inc
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.7.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.7.2 Business Overview
-
8.2.7.3 Financials (Subject to data availability)
-
8.2.7.4 Product Types Specification
-
8.2.7.5 Business Strategy
-
8.2.7.6 S.W.O.TAnalysis
-
-
8.2.8 AyuVis Research Inc.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.8.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.8.2 Business Overview
-
8.2.8.3 Financials (Subject to data availability)
-
8.2.8.4 Product Types Specification
-
8.2.8.5 Business Strategy
-
8.2.8.6 S.W.O.TAnalysis
-
-
8.2.9 AntlerA
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.9.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.9.2 Business Overview
-
8.2.9.3 Financials (Subject to data availability)
-
8.2.9.4 Product Types Specification
-
8.2.9.5 Business Strategy
-
8.2.9.6 S.W.O.TAnalysis
-
-
This chapter would comprehensively cover market drivers, trends, restraints, opportunities, and various in-depth analyses like industrial chain, PESTEL, Porter’s Five Forces, and ESG, among others. It would also include product life cycle, technological advancements, and patent insights.
Chapter 9 Qualitative Analysis (Subject to Data Availability)
-
9.1 Market Drivers
-
9.2 Market Restraints
-
9.3 Market Trends
-
9.4 Market Opportunity
-
9.5 Technological Road Map (Subject to Data Availability)
-
9.6 Product Life Cycle (Subject to Data Availability)
-
9.7 Consumer Preference Analysis
-
9.8 Market Attractiveness Analysis
-
9.9 PESTEL Analysis
-
9.9.1 Political Factors
-
9.9.2 Economic Factors
-
9.9.3 Social Factors
-
9.9.4 Technological Factors
-
9.9.5 Legal Factors
-
9.9.6 Environmental Factors
-
-
9.10 Industrial Chain Analysis (Subject to Data Availability)
-
9.10.1 Industry Chain Analysis
-
9.10.2 Manufacturing Cost Analysis
-
9.10.3 Supply Side Analysis
-
9.10.3.1 Raw Material Analysis
-
9.10.3.2 Raw Material Procurement Analysis
-
9.10.3.3 Raw Material Price Trend Analysis
-
-
-
9.11 Porter’s Five Forces Analysis
-
9.11.1 Bargaining Power of Suppliers
-
9.11.2 Bargaining Power of Buyers
-
9.11.3 Threat of New Entrants
-
9.11.4 Threat of Substitutes
-
9.11.5 Degree of Competition
-
-
9.12 Patent Analysis (Subject to Data Availability)
-
9.13 ESG Analysis
Segmentation Type Analysis 2019 -2031, will provide market size split by Type. This Information is provided at Global Level, Regional Level and Top Countries Level The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 10 Market Split by Type Analysis 2019 -2031
-
10.1 Laser Treatment
-
10.1.1 Global Retinopathy Of Prematurity Therapeutics Revenue Market Size and Share by Laser Treatment 2019 -2031
-
-
10.2 Injection
-
10.2.1 Global Retinopathy Of Prematurity Therapeutics Revenue Market Size and Share by Injection 2019 -2031
-
-
10.3 Eye Surgery
-
10.3.1 Global Retinopathy Of Prematurity Therapeutics Revenue Market Size and Share by Eye Surgery 2019 -2031
-
-
10.4 Others
-
10.4.1 Global Retinopathy Of Prematurity Therapeutics Revenue Market Size and Share by Others 2019 -2031
-
The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 11 Market Split by Application Analysis 2019 -2031
-
11.1 Hospital
-
11.1.1 Global Retinopathy Of Prematurity Therapeutics Revenue Market Size and Share by Hospital 2019 - 2031
-
-
11.2 Clinic
-
11.2.1 Global Retinopathy Of Prematurity Therapeutics Revenue Market Size and Share by Clinic 2019 - 2031
-
-
11.3 Home Care
-
11.3.1 Global Retinopathy Of Prematurity Therapeutics Revenue Market Size and Share by Home Care 2019 - 2031
-
The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 12 Market Split by End-User Analysis 2019 -2031
-
12.1 Hospitals
-
12.1.1 Global Retinopathy Of Prematurity Therapeutics Revenue Market Size and Share by Hospitals 2019 -2031
-
-
12.2 Ophthalmic Clinics
-
12.2.1 Global Retinopathy Of Prematurity Therapeutics Revenue Market Size and Share by Ophthalmic Clinics 2019 -2031
-
-
12.3 Ambulatory Surgical Centers
-
12.3.1 Global Retinopathy Of Prematurity Therapeutics Revenue Market Size and Share by Ambulatory Surgical Centers 2019 -2031
-
This chapter helps you understand the Key Takeaways and Analyst Point of View of the global Retinopathy Of Prematurity Therapeutics market
Chapter 13 Research Findings
-
13.1 Key Takeaways
-
13.2 Analyst Point of View
Here the analyst will summarize the content of entire report and will share his view point on the current industry scenario and how the market is expected to perform in the near future. The points shared by the analyst are based on his/her detailed in-depth understanding of the market during the course of this report study. You will be provided exclusive rights to interact with the concerned analyst for unlimited time pre purchase as well as post purchase of the report.
-
13.3 Assumptions and Acronyms
Sample Format of Deliverables
The Tables, Graphs/Charts are only for representative purposes and do not depict actual statistics. Purchase full Report access to actual data.
Qualitative Analysis
Research Methodology Implemented by Manjiri Kanhere and Team
- 1.1 Retinopathy Of Prematurity Therapeutics Market Report 2024 Research Methodology
- 1.2 Systematic Research Approach
- 1.2.1 Primary Research for Retinopathy Of Prematurity Therapeutics Market
- 1.2.1.1 Key Data from Primary
- 1.2.1.2 Primary Interviews with Experts
- 1.2.1.3 Key Industry Insights
- 1.2.1.4 Questionnaire for Retinopathy Of Prematurity Therapeutics Market
- 1.2.1.5 Breakdown of Primaries
- 1.2.2 Secondary Research for Retinopathy Of Prematurity Therapeutics Market
- 1.2.2.1 Key Data from Secondary
- 1.2.2.2 Paid Sources
- 1.2.2.3 Public Sources
- 1.3 Market Size Estimation for Retinopathy Of Prematurity Therapeutics Market
- 1.3.1 Top-Down Approach
- 1.3.1.1 Analyzing Market Size by Top-Down Approach (Supply Side)
- 1.3.2 Bottom-UP Approach
- 1.3.2.1 Analyzing Market Size by Bottom-Up Approach (Demand Side)
- 1.3.1 Top-Down Approach
- 1.4 Market Breakdown and Data Triangulation
- 1.5 Research Assumptions for Retinopathy Of Prematurity Therapeutics Market
Key Questions Answered By Retinopathy Of Prematurity Therapeutics Market Report 2024
| Why Laser Treatment have a significant impact on Retinopathy Of Prematurity Therapeutics market? |
| What are the key factors affecting the Laser Treatment and Injection of Retinopathy Of Prematurity Therapeutics Market? |
| What is the CAGR/Growth Rate of Hospital during the forecast period? |
| By type, which segment accounted for largest share of the global Retinopathy Of Prematurity Therapeutics Market? |
| Which region is expected to dominate the global Retinopathy Of Prematurity Therapeutics Market within the forecast period? |
| Segmentation Level Customization |
|
| Global level Data Customization |
|
| Region level Data Customization |
|
| Country level Data Customization |
|
| Company Level |
|
| Additional Data Analysis |
|
| Additional Qualitative Data |
|
| Additional Quantitative Data |
|
| Service Level Customization |
|
Report Format Alteration |
|
